Oberweis Asset Management Inc Biocryst Pharmaceuticals Inc Transaction History

Oberweis Asset Management Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2018 Aug 14, 2018	SELL	$4.6 - $6.52 $110,399 - $156,480	-24,000 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$4.35 - $5.82 $28,709 - $38,412	-6,600 Reduced 21.57%	24,000 $114,000
Q4 2017 Feb 14, 2018	BUY	$4.16 - $5.33 $56,160 - $71,955	13,500 Added 78.95%	30,600 $150,000
Q3 2017 Nov 13, 2017	BUY	$4.1 - $5.97 $70,110 - $102,087	17,100	17,100 $90,000

279

169M

930K

1.03M

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.68B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Oberweis Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Oberweis Asset Management Inc with notifications on news.